Under its medical brand Feelicare, Feeligreen develops innovative medical devices improving everyday’s quality of life for patients facing chronic diseases.
In the medical devices market segment, which has shown steady growth over the past 5 years, Feeligreen unique platform technologies can be configured to target multiple pathologies. These innovations, demanded by the healthcare industry, will extend the lifespan of a wide range of existing treatments.
Our devices use cloud technology to monitor treatment compliance and allow healthcare professionals to provide customised treatment to their patients.
Winner of the Innovation World Cup 2014/2015 in the “healthcare and wellness” category, Feelicare is actively working on several therapeutic applications, combining multiple technologies such as iontophoresis and photodynamic therapy.
Feeligreen is currently developing an autonomous and secure programmable device (rechargeable) that combines the use of iontophoresis, thereby improving transdermal delivery of active drugs and a programmable technology for photodynamic therapy that can be adapted to the wavelength required for the treatment of various dermatological conditions.
Feeligreen has signed strategic partnerships with leading private and public partners such as the University of Nice Sophia Antipolis, the National Center for Scientific Research (CNRS), and pharmaceutical and cosmetic laboratories including the Pierre Fabre group and Galderma.
Feeligreen awards and publications in the medical field:
2014/2015: Innovation World Cup in the “healthcare and wellness” category.
2015: Grand winner of the e-Health Summer University competition, held in Castres and sponsored by the Pierre Fabre laboratories, for two projects: chronic arthritic knee-pain treatment and a portable device for combined treatment of localized psoriasis.
Geographic location influence the likelihood of having psoriasis; disease prevalence increases with distance from the equator, and more than 2.5 million people suffer from psoriasis in France. Many are subject to stigma and discrimination, an aggravating situation: 4 out of 10 French say they prefer to keep their distance from people with psoriasis and 5% of the French population still think that psoriasis is contagious, according to a recent study.
This non-contagious illness occurs on a genetic predisposition factors associated with environments (stress, infections, drugs, etc…). Psoriasis is a skin disease that affects men, women, children or infants. Psoriasis can occur at any age. Generally benign, this disease is very likely to seriously impair patients’ quality of life. Phototherapy is considered the first-line treatment of extensive and severe psoriasis cases. However the frequency of sessions (3 per week as usually recommended) can be a drag. Indeed it is not always compatible with patient’s place of residence or work, however compliance is a key factor in the management of psoriasis. Topical treatments are also considered first order treatments (dermocorticoid or analogue of vitamin D) or second line (retinoide) and the association of these treatments with phototherapy has been showing promising results in recent studies.
Measuring patient’s compliance to the prescribed treatment, and the ability to customize the treatment protocol are keys to success in the treatment of psoriasis.
Feeligreen’s research & development is leveraging its technology platform and product portfolio to construct an autonomous and secure programmable device for multiple dermatological treatments.
Bedsore is a cutaneous ischemic lesion related to compression of the soft tissues between a hard surface and bony prominences. According to the Classification of the National Pressure Ulcer Advisory Panel there are four levels of ulcer development:
Pressure ulcers cause pain, discomfort, pain and suffering, a limitation of functional capacity. Bedsores also result in impaired self-image and relationships with others related to the presence of the wound.
Pressure ulcer is responsible for an increased use of care and resources. According to a Dutch study: the costs involved in the management of pressure ulcers were third after cancer and cardiovascular disease. They estimate more than 50 000 euros the average cost of caring for a developped bedsore. The estimated cost of prevention per patient per day ranges from € 2.65 to € 87.57 in all environments.
Its frequency is little known today and varies according to clinical situation. However bedsores can be prevented in most cases. The establishment of general preventive measures starts from the identification of risk factors. Thus the establishment of a support adapted to aid in the prevention and treatment of pressure ulcers is one of the top priorities to reduce pressure between the skin and the patient support and facilitate recovery of mobility.
It is in this context that Feeligreen is currently engaged in several projects, targeting the detection and prevention of pressure ulcers as well as the management of existing ulcers.
Vitiligo is a chronic skin disease characterized by a patchy loss of skin color. Vitiligo affects a significant percentage of the world population, at a rate of 0.5% to 2% of the population depending on the study. It affects people of all ages and ethnic origin, more than half of them developing the skin condition before the age of 20 years. It is estimated that 1 to 2% of the population is affected in Europe. In France, there is between 900,000 and 1.2 million people affected by vitiligo.
Vitiligo is a disease that can have profound psychological consequences, it is now well demonstrated that vitiligo often significantly impacts the lives of people who suffer from this condition, causing intense psychological disturbances and a significant decrease in quality of life.
The gradual depigmentation of the skin which characterizes vitiligo is associated with the loss of melanocytes in the basal layer of the epidermis. There are two main types: generalized vitiligo (the common symmetric shape) and segmental (affecting only one side of the body). Narrow spectrum UVB and class 3 corticosteroids are considered the reference treatments respectively for the vulgar vitiligo generalized and localized. Lamps delivering narrow spectrum 308nm UVB light showed high levels of repigmentation in localized vitiligo. The value of combining topical corticosteroids with phototherapy has recently been reported. These combined treatments offer better results than monotherapy and should be offered as first line in difficult areas to be treated such that the ends or bony prominences. However, current therapies require months or years of treatment and sometimes lead to disappointing results. There is a strong patient demand for phototherapy at home. Allowing the patient to receive effective and secure treatment while measuring adherence is a guarantee of success in the treatment of vitiligo.
This project aims to design an autonomous and secure programmable device that incorporates critical functionalities such as compliance and the integration of treatment customization, whether performed by dermatologist practitioner or by the patient as a home care device, leveraging a e-Health data and communication infrastructure.
Osteoarthritis is responsible for severe morbidity in developed countries where it is the second cause of disability after cardiovascular diseases. It represents about 13 million medical consultation per year in France. Due to the aging population, its prevalence is steadily increasing, currently estimated at about 17%. Within the 9 to 10 million people affected, 4.6 million suffer from symptomatic osteoarthritis. In 2002, the direct costs associated with osteoarthritis amounted to over 1.6 billion euros (about 1.7% of the total budget of national healthcare). Half of these costs are attributed to the patient management at the hospital, and about 570 million euros are allocated to drug prescription (1) (2).
Osteoarthritis commonly affects certain joints, particularly the knee. The annual incidence of symptomatic knee osteoarthritis is 240 cases per 100 000 person-years. The prevalence of knee osteoarthritis has rarely been described and published and figures vary depending on the definition of the disease (radiological criteria, clinical, or mixed); however, in the 65-75 age group, for women, the prevalence of radiographic evidence of OA is estimated at 35%. Improving the quality of life (QoL) of patients with osteoarthritis is the 87th target in the list of 100 priorities for public health set by the French law of 9 August 2004.
Osteoarthritis is also a chronic disease that once declared, persists. No curative treatment is available at present, but there are ways to act on its main symptom: pain. The management of a patient with knee OA is multifactorial. The main objective is to address the concerns of those patients including pain relief and improved joint mobility, in order to reduce disability and improve their quality of life (3).
As far as drug therapy is concerned, the HAS (National Healthcare Authority) recommends as a first intention oral prescription of paracetamol, or tier I painkillers (4). Non-steroidal anti-inflammatory drugs (NSAIDs) should only be used during painful flare-ups not responding to paracetamol.
Thus the use of a micro-current device for delivering an anti inflammatory drug (NSAID) could be the missing link between the use of oral opiated treatments, often deleterious, and the use of simple topical treatments, concurring to a satisfactory level of effectiveness and utmost tolerance.